Previous 10 | Next 10 |
Announces Pricing of $35 Million Aggregate Principal Amount Offering of 11.875% Senior Notes Due 2027 Harrow Health, Inc. (Nasdaq: HROW), an eyecare pharmaceutical company exclusively focused on the discovery, development, and commercialization of innovative ophthalmic prescription ther...
Eyecare pharmaceutical company Harrow Health ( NASDAQ: HROW ) announced an agreement on Wednesday to acquire the exclusive U.S. commercial rights to several FDA‑approved ophthalmic products from Novartis ( NYSE: NVS ) ( OTCPK:NVSEF ). The deal, expected to close in ...
Harrow Health ( NASDAQ: HROW ) has announced the pricing of an underwritten registered offering of 2,376,426 shares of its common stock. Each share is being issued at $10.52 for aggregate gross proceeds of $25M. The eyecare pharmaceutical company expects to use the net proceed...
Harrow Health, Inc. (Nasdaq: HROW), an eyecare pharmaceutical company exclusively focused on the discovery, development, and commercialization of innovative ophthalmic prescription therapies, today announced that it has commenced an underwritten registered public offering of $100 million aggregat...
Harrow Health, Inc. (Nasdaq: HROW), an eyecare pharmaceutical company exclusively focused on the discovery, development, and commercialization of innovative ophthalmic prescription therapies, today announced that it priced an underwritten registered offering of 2,376,426 shares of its common stoc...
Harrow (Nasdaq: HROW), an eyecare pharmaceutical company exclusively focused on the discovery, development, and commercialization of innovative ophthalmic therapies, today announced that it has entered into a binding agreement for the acquisition of the exclusive U.S. commercial rights to five FD...
Harrow (Nasdaq: HROW), an eyecare pharmaceutical company exclusively focused on the discovery, development, and commercialization of innovative ophthalmic prescription therapies, and iOR Partners, the pioneer in office-based surgery in the field of ophthalmology, today jointly announced the expan...
Sienna Harrow Health, Inc. (HROW) Q3 2022 Earnings Conference Call November 14, 2022 4:45 PM ET Company Participants Jamie Webb – Director-Communications and Investor Relations Mark L. Baum – Chief Executive Officer Andrew Boll – Chief Financ...
Harrow Health press release ( NASDAQ: HROW ): Q3 GAAP EPS of -$0.24 misses by $0.23 . Revenue of $22.8M (+21.9% Y/Y) misses by $0.34M . For further details see: Harrow Health GAAP EPS of -$0.24 misses by $0.23, revenue of $22.8M misses by $0.34M
Selected Recent Highlights: FDA approval of IHEEZO™ for ocular surface anesthesia Launch of Fortisite™, fortified antibiotics Launch of atropine.com™ compounded atropine portal Revenues of $22.8 million, up 22% over $18.7 million for the prior ...
News, Short Squeeze, Breakout and More Instantly...
Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced that its management team would attend the 2024 American Society of Retina Specialists (ASRS) Annual Meeting, taking place in Stockholm, Sweden, from July 17-20, 2024. The ASRS Annual Meeting brings tog...
Contract Enhances Purchasing Power for 340B Prime Vendor Program (PVP) Participants; Aligns with Harrow’s Mission to Make Its Products Accessible and Affordable Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced that as of July 1, 2024, ...